998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study
Oliver Klein(Berlin-Brandenburger Centrum für Regenerative Therapien), M.S. Carlino, D. Thomas(UNSW Sydney), Damien Kee(Peter MacCallum Cancer Centre), Jonathan Cebon(La Trobe University), Ian Collins(St. James's Hospital), W-S. Lam(Fiona Stanley Hospital), Martha E. Brown(Royal Adelaide Hospital), Henry Chan(Calvary Mater Newcastle Hospital), Jamie Palmer(Olivia Newton-John Cancer Wellness & Research Centre), S.J. Harris(Bendigo Health), Bo Gao(Sun Yat-sen University), Jimmy Bok Yan So(National University of Singapore), Michael Michael(Ospedale San Donato), Ken Wilkie(Olivia Newton-John Cancer Wellness & Research Centre), Schiffon Wong(Barwon Health), Megan Lyle(Queensland Health), Craig Underhill(AstraZeneca (United Kingdom)), R. Zielinski(Western NSW Local Health District), Rosemary Harrup(University of Tasmania)
Cited by 1
Related Papers
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
|Proceedings of the National Academy of Sciences|2004|440
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
|Journal of Clinical Oncology|2011|433